Epidemiological Study in FRONtoTemporal Dementia (EFRONT)

April 7, 2026 updated by: CENTOGENE GmbH Rostock
An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal and temporal lobes. This leads to abnormalities in behaviour, personality, and language comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity, difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial aggregation). For this study, blood samples were collected from clinically diagnosed or suspected FTD patients and were analysed for a broad range of pathogenic variants in genes associated with FTD. The scientific insights acquired from this study will help identify novel therapeutic targets and develop/ investigate potential disease-modifying drugs.

Study Type

Observational

Enrollment (Actual)

2287

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Liège, Belgium, 4000
        • CHU de Liège
    • West Flanders
      • Ostend, West Flanders, Belgium, 8400
        • AZ Damiaan
  • Germany
      • Aachen, Germany, 52074
        • RWTH Aachen University
      • Bad Homburg, Germany, 61352
        • Hochtaunus-Kliniken gGmbH
      • Berlin, Germany, 12200
        • AGZ of Charite Universitätsmedizin Berlin
      • Cologne, Germany, 50937
        • University Hospital Cologne
      • Hamburg, Germany, 22419
        • Asklepios Klinik Nord - Ochsenzoll
      • Rostock, Germany, 18057
        • University Hospital Rostock
    • Hesse
      • Hanau, Hesse, Germany, 63450
        • Hanau Hospital
      • Leun, Hesse, Germany, 35638
        • Gertrudis Klinik
    • Saxony
      • Dresden, Saxony, Germany, 01307
        • University Hospital Dresden
    • Schleswig-Holstein
      • Hamburg, Schleswig-Holstein, Germany, 20246
        • University Medical Center Hamburg Eppendorf
      • Lübeck, Schleswig-Holstein, Germany, 23562
        • University of Lubeck
  • Greece
      • Athens, Greece, 16675
        • Mediterraneo Hospital
      • Ioannina, Greece, 45110
        • University of Ioannina
  • Italy
      • Chieti, Italy, 66100
        • Università degli studi Gabriele D'Annunzio Chieti-Pescara
      • Naples, Italy, 80131
        • Azienda Ospedaliera Universitaria Federico II Di Napoli
      • Parma, Italy, 43126
        • Azienda Ospedaliero-Universitaria di Parma
      • Reggio Emilia, Italy, 42121
        • Azienda USL-IRCCS of Reggio Emilia
  • Portugal
      • Almada, Portugal, 2805-267
        • Hospital Garcia de Orta
      • Coimbra, Portugal, 3000-606
        • Unidade Psiquiatrica Privada de Coimbra
      • Guimarães, Portugal, 4835-044
        • Hospital Da Senhora Da Oliveira Guimarăes
      • Loures, Portugal, 2674-514
        • Hospital Beatriz Ângelo
      • Matosinhos Municipality, Portugal, 4464-513
        • Hospital Pedro Hispano
      • Torres Vedras, Portugal, 2560-280
        • CNS - campus neurológico Torres Vedras
  • Spain
      • Barcelona, Spain, 08035
        • Hospital Universitari Vall d´Hebrón
      • Madrid, Spain, 28040
        • Hospital Clinico San Carlos
      • Madrid, Spain, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Spain, 28006
        • Universitary Hospital La Princesa
      • Pamplona, Spain, 31008
        • Clinica Universidad de Navarra
      • Santander, Spain, 39011
        • Marqués de Valdecilla University Hospital
  • Turkey (Türkiye)
      • Ankara, Turkey (Türkiye), 06100
        • Hacettepe University
      • Ankara, Turkey (Türkiye), 06100
        • Baskent University
      • Istanbul, Turkey (Türkiye), 34010
        • Koç University Hospital
      • Istanbul, Turkey (Türkiye), 34093
        • Bezmialem Vakif University
      • Istanbul, Turkey (Türkiye), 34080
        • Istanbul University
      • Izmir, Turkey (Türkiye), 35575
        • Izmir Economy University Medikalpark Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Participants diagnosed with Frontotemporal Dementia (FTD) and participants clinically suspected for FTD

Description

Inclusion Criteria:

  • Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian
  • The participant is aged between 25 to 85 years
  • The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Participants diagnosed with Frontotemporal Dementia
Diagnostic test: Genetic Screening
Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants
Time Frame: 15 months
15 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

CENTOGENE GmbH Rostock

Investigators

  • Principal Investigator: Peter Bauer, Ph.D, CENTOGENE GmbH

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2021

Primary Completion (Actual)

January 9, 2024

Study Completion (Actual)

January 9, 2024

Study Registration Dates

First Submitted

September 30, 2021

First Submitted That Met QC Criteria

September 30, 2021

First Posted (Actual)

October 12, 2021

Study Record Updates

Last Update Posted (Actual)

April 9, 2026

Last Update Submitted That Met QC Criteria

April 7, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EFRONT 05-2021

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Frontotemporal Dementia

Clinical Trials on Genetic Screening

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe